Antisoma (LSE: ASM.L - news) shares could double if the ovarian cancer drug, R1549, is successful, and halve if it is not says the Independent. Given the probability of success, reckoned to be about 65%, that looks a gamble worth taking says the paper.

Investors Chroncile - 23 February 2007

ANTISOMA (ASM)

"Everything is going swimmingly," boasts Antisoma chief executive Glyn Edwards. Certainly, the outlook has improved dramatically since Roche decided not to option lung-cancer drug AS1404 last June. At the time, Mr Edwards insisted there would be considerable licensing interest from other parties, and he has been proved right. Antisoma says licensing discussions with several parties are heating up. The plan is to finalise a deal by the end of June this year.

And Phase II trial data has been impressive. Average survival of patients receiving the drug alongside chemotherapy was 14 months, compared with 8.8 months for those on chemotherapy only - one of the biggest increases in survival ever seen in a lung-cancer study. If data from trials in prostate cancer is also good, this could extend the potential market for the drug.

More good news

http://moneyam.uk-wire.com/cgi-bin/articles/20070308070000H0273.html

Legal & General Group, acquisition of Shares

http://moneyam.uk-wire.com/cgi-bin/articles/20070315121500H2145.html

Could break the 50p today.

Looks like it break the 50p today.

UK Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Chief Executive Officer, Glyn Edwards, will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York on Wednesday 11 April.


http://www.veracast.com/cibcwm/biotech07/main/player.cfm?eventName=1141_antiso&appname=Microsoft Internet Explorer&os=Windows XP&wmversion=Yes - version 11.0.5721.5145&rmversion=Yes - version 6.0.12.1483

52p area is a historical resistance level - hit in Oct '01, Oct '03 and Apr '04.

Steve

London, UK, and Los Angeles, CA: 16 April 2007- Antisoma announces
that preclinical data supporting three of its drugs are presented
this week at the Annual Meeting of the American Association of Cancer
Research (AACR).

AS1404-Avastin-paclitaxel triple combination highly effective
Antisoma's scientists have for the first time evaluated a triple
combination of the Company's vascular disrupting agent, AS1404, the
anti-angiogenic Avastin and the chemotherapy drug paclitaxel. The
triple combination had powerful and synergistic (more than additive)
anti-tumour effects in a human lung cancer xenograft model. Moreover,
addition of Avastin and paclitaxel to AS1404 did not increase
toxicity.

These observations build on previous xenograft findings showing a
synergistic effect with an AS1404-paclitaxel combination. That effect
translated into a substantial survival benefit in a phase II trial in
non-small cell lung cancer. Preparations are being made for a pivotal
phase III trial combining AS1404 with chemotherapy in lung cancer.
The market opportunity in this setting is large, and would be further
extended if AS1404 also proved effective when added to an
Avastin-chemotherapy combination.

Synergistic effect of AS1404 combined with Erbitux
In a second combination study, AS1404 showed synergistic anti-tumour
effects with Erbitux in a lung cancer model. These findings, together
with the Avastin data, show that AS1404 has potential in combination
with newer, targeted therapies as well as longer established
treatments such as chemotherapies.

Broad potential of AS1411 alone and in combination
New data show that the aptamer drug AS1411 kills cells from a wide
variety of cancer cell lines. These include lines representing the
four most common cancers: lung, breast, prostate and colorectal; as
well as renal, gastric, pancreatic, melanoma, glioblastoma and
certain blood cancer lines. Doses lethal to cancer cells had no
effect on a fibroblast cell line representing normal, healthy tissue.

Separate experiments highlight the potential to combine AS1411 with
other treatments. When AS1411 was used together with paclitaxel or
cytarabine, synergistic killing was seen in a number of cancer cell
lines.

New light is shed on the anti-cancer action of AS1411. The drug
clearly induces apoptosis (programmed cell death). There are,
however, differences from the killing pattern seen with many
cytotoxic drugs, which generally achieve their maximum effect
rapidly. By contrast, AS1411 acts more slowly, continuing to cause
further cell death over a period of days.

AS1411 has completed phase I development, where it was shown to be
very well-tolerated and produced two objective responses in
late-stage renal cancer patients. Phase II trials in renal cancer and
acute myeloid leukaemia (AML) are now planned and the drug may
ultimately have potential against a variety of solid and blood
cancers.

Preclinical support for AS1409 trial plans
Antisoma recently announced that its forthcoming phase I trial of
AS1409, an antibody-cytokine fusion protein, would enrol patients
with renal cancer and melanoma. An AACR poster presents the data
which supported this choice, showing strong expression of the drug's
target in both of these cancer types.

Glyn Edwards, Antisoma's CEO, said: "Our AACR presentations
illustrate the strength and breadth of our pipeline and highlight a
number of ways to further expand the commercial opportunities for our
key products, AS1404 and AS1411."

Antisoma says successfully tests cancer drugs in combination with others

http://www.moneyam.com/action/news/showArticle?id=1903770

Blue
Posted at the same time, all still looking good 1 next target.

No problem driver,

I have read the AFX report but I know that in theory we are not allowed to paste it due to copyright infringement so I did the other one!!!!

Blue
I don't think there is a problem, it is on this site after all.

400k buy today is there news soon?

Certainly was Driver!

http://moneyam.uk-wire.com/cgi-bin/articles/20070419064500H9831.html

Steve

Good news as Steve said.

Antisoma to get 100 mln usd near-term in licensing deal with Novartis UPDATE
AFX

LONDON (Thomson Financial) - Antisoma plc said it stands to receive near term payments of 100 mln usd under an exclusive global licensing agreement signed with Novartis AG for its vascular disrupting agent AS1404 (DMXAA).

Some 75 mln usd will be paid immediately and a further 25 mln when AS1404 enters a phase III trial in lung cancer.

Antisoma will be eligible for total upfront, development, regulatory and sales-related milestone payments of up to 890 mln usd, depending upon a number of factors including successful development and marketing of AS1404 in

multiple indications, launch of back-up products and achievement of sales milestones.

Antisoma will also benefit from Novartis part-funding its commercialisation costs if AS1404 gets to market. Under the deal with Novartis, if AS1404 is approved and commercialised, Antisoma will receive royalties on AS1404 sales and will have an option to co-commercialise AS1404 in the United States.

The group said the deal with Novartis is an important step along the way to making Antisoma a significant and self-sustaining bio-pharmaceutical company.

It said it plans an active programme of in-licensing and to examine opportunities to acquire other oncology companies.

Antisoma is also continuing to evaluate a potential US listing which it said would broaden the capital base supporting the company's development.

The board said it intends to continue to develop AS1411 independently and will also consider potential sales synergies when seeking new assets for the pipeline.

Antisoma said its board intends to discuss its plans with shareholders and resolutions supporting the plans will be put to an EGM.

They will include a renewal of the company's authority to issue new shares up to around a third of the issued number. The board is also minded to seek a renewal of its authority to issue shares for cash in a non-pre-emptive issue, it said. This would provide flexibility, for example to offer new shares as American Depositary Receipts (ADRs) should the board decide to list the company in the US.

Looking forwards, chairman Barry Price said the period ahead will be an exciting one.

'We have formed a great partnership with Novartis to develop and commercialise AS1404. Further important phase II data on AS1404 are expected this year. Other drugs in our pipeline, notably AS1411, are showing real promise. We are now very well equipped to acquire and develop new products and to continue to grow the business.'

Yep been waiting a long time for this ASM have pulled of a very good deal for them and us, the sp could double or treble from here over the next year or so.

There has been some very large buys today I can see this moving slowly up over the next few weeks as investors see the future potential of ASM, with more products in the pipe line.

Looks like 60p is acting as resistance, and I guess short-term holders have been taking profits too.

Steve

There was 3*1m buys today and a lot of over 100k's that's good enough for me this is a hold or accumulate.

More profit-taking today, or a closing of yesterday's gap up? I must admit, I thought this would have ticked up today. I guess the volume is comparatively low.
Anybody know if the Novartis news was in today's papers?

Steve

The Times -Buy
April 20, 2007
Antisoma

It has been a rough ride, at times, for shareholders in this biotechnology group. The share price quadrupled between autumn 2003 and spring 2004 as the market enjoyed promising news flow. In April 2004, however, the shares collapsed when it encountered setbacks in its research programme and the dissolution of a development deal with Roche.

Confidence began to be rebuilt with a successful cash call in late 2005 and news yesterday of a new link, this time with Novartis, has helped the stock recover lost ground.

The Novartis deal, including 50 million in upfront and near-term payments, secures Antisomas finances for the forseeable future and opens potential market opportunities in the US. Hopes are that Antisoma will be able to bring forward several compounds, designed to treat different cancers. As with many biotechs, the risks are high. But so are the rewards. Buy

http://business.timesonline.co.uk/tol/business/columnists/article1680463.ece